Navigation Links
Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
Date:8/26/2013

RYE, N.Y., Aug. 26, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced today that it has entered into a collaborative research agreement with the VTT/MSI Molecular Sciences Institute (MSI) in Berkeley, CA.

Founded in 1996 by Nobel-prize winner Sydney Brenner, MSI is an independent, not-for-profit research institute. In 2011, MSI created a partnership in bioengineering with VTT (Technical Research Centre of Finland) that is now known as the VTT/MSI Molecular Sciences Institute. VTT/MSI's Center for Bioengineering strives to contribute to the understanding of biology to improve human health and positively impact society.

Curemark's Chief Scientific Officer Dr. Matthew Heil said, "Tapping into MSI's expertise will deepen our knowledge of the full nature of our proprietary enzyme's biological properties.  We expect this research will lead to multiple additional indications and formulation possibilities, which will benefit people with unmet medical needs."

Dr. Orna Resnekov, VTT/MSI Director, echoed Dr. Heil's sentiments. "We are excited to work with Curemark, the leader in novel therapies for autism, to advance the company's exciting research and development program," she said.

Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation.  The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.

Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company's New Drug Application (NDA) for CM-AT.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company's innovative science, visit www.curemark.com.

Safe-Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
2. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
3. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
4. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
5. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
6. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
7. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
8. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
9. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
10. Eqalix Enters Sponsored Research Agreement with Temple University
11. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... in recruiting top industry experts, and expanding its LATAM network and logistics capabilities. ... for clients to manage their clinical trial projects. , The expansion will provide ...
(Date:4/27/2016)... York, NY (PRWEB) , ... April 27, 2016 ... ... realizing it. Touch screen mobile devices with fingerprint recognition for secure access, ... libraries are only a few ways consumers are interacting with biometrics technology today. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use ... , PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, ...
(Date:4/27/2016)... 2016 ReportsnReports.com adds 2016 ... focus on US, EU, China ... the healthcare business intelligence collection of its growing ... report on the Flow Cytometry market spread across ... 282 tables and figures is now available at ...
Breaking Biology Technology:
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
Breaking Biology News(10 mins):